Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT101 Combined With Mitoxantrone Liposome in Recurrent/Metastatic Nasopharyngeal Cancer
NCT06892431Phase 2Not yet recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of becotatug in nasopharyngeal carcinoma (NPC) (3 arms), sponsored by Shanghai Jinmante Biotechnology Co., Ltd. Primary endpoint: Objective Response Rate at 30 months. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
becotatug
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06892431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892431.